Key facts
- Moderna's experimental cancer vaccine combined with Merck's Keytruda showed a 49% reduction in melanoma recurrence and death risk.
- The risk reduction was observed over a five-year observation period.
- The treatment utilizes the patient's immune system to attack cancer cells.
- The study focused on melanoma, a type of skin cancer.
This study highlights a significant advancement in melanoma treatment, showcasing the potential of immunotherapy combinations. The sustained reduction in recurrence and death risk over five years suggests a durable immune response, offering new hope for patients with advanced skin cancer.